



## Meeting with EFPIA on future priorities of EU trade policy

### Meeting date and place

Meeting held on 29/01/2020 11:30 in Charlemagne

### Participating organisation(s) & representative(s)

[Art. 4.1 (b)]	[Art. 4.1 (b)] - European Federation of Pharmaceutical Industries and Associations (TRN: 38526121292-88)	<b>Participant. Requester. Contact.</b>
[Art. 4.1 (b)]	-- European Federation of Pharmaceutical Industries and Associations (TRN: 38526121292-88)	<b>Participant.</b>
[Art. 4.1 (b)]	-- European Federation of Pharmaceutical Industries and Associations (TRN: 38526121292-88)	<b>Participant.</b>
[Art. 4.1 (b)]	[Art. 4.1 (b)] - European Federation of Pharmaceutical Industries and Associations (TRN: 38526121292-88)	<b>Participant.</b>

### Main issues discussed

EFPIA made the following points:

- Priority countries for EFPIA are the US, China, Turkey, Russia, Japan (and Switzerland).
- In addition to their general IP concerns (they were very appreciative of our last IP report which well reflected their input), they are currently worried by US - and the possibility that the sector could be hit by tariffs from either side.
- [Art. 4.2 first indent]
- They expect EU's trade policy to:
  - Project an open and innovation friendly image around the world. They fear that the turn in international stability may lead to a protectionist trade policy.
  - Defend IP.
  - Project EU standards globally
  - Be able to enforce properly trade agreements (strong interest/high expectation on CTEO)
- They enquired when the new communication on trade and investment policy would be issued and how they could be involved in the process.
- Brexit: Very interested, in particular in MRA in their sector.

On Brexit, [Art. 4.1 (b)] clarified that a new structure was being set up as negotiations will start and that Unit G1 was no longer in charge of BREXIT related issues (referring to [Art. 4.1 (b)]). She then presented the new priorities of EU trade policy that are emerging and explained that we are at anytime open for contributions form stakeholders, especially now that we are starting a new institutional cycle.

### Directorate or unit

TRADE G/1

### Internal participants

[Art. 4.1 (b)]	TRADE G/1	[Art. 4.1 (b)] @ec.europa.eu	<b>Participant.</b>
[Art. 4.1 (b)]	TRADE G/1	[Art. 4.1 (b)] @ec.europa.eu	<b>Participant. Notetaker.</b>
[Art. 4.1 (b)]	TRADE G/3	[Art. 4.1 (b)] @ec.europa.eu	<b>Participant.</b>

### Author(s) of minutes

[Art. 4.1 (b)]

### Validator and validation date

[Art. 4.1 (b)] validated the minutes on 13/02/2020 13:34